CYFRA 21-1, SERUM

The CYFRA 21-1 test measures levels of a protein fragment released by lung cancer cells. It is used as a tumor marker for non-small cell lung cancer (NSCLC) and helps monitor disease progression or response to therapy.

Available via

Home Collection, Lab Visit

Contains

1 parameters

Earliest reports in

Same Day

Test details

CYFRA 21-1, SERUM Test in New Delhi Overview

Preparations

No special preparations needed

Test included
CYFRA 21-1, SERUM includes 1 parameter

  • Cyfra 21-1
Frequently Asked Questions

CYFRA 21-1 is a tumor marker test used primarily to monitor non-small cell lung cancer (NSCLC), especially squamous cell carcinoma. It measures a fragment of cytokeratin 19 found in the blood, which is released by cancerous cells. Elevated levels of CYFRA 21-1 may indicate the presence or progression of certain types of cancers.

The test requires a blood sample drawn from a vein in the arm. This sample is then analyzed in a laboratory to measure the level of CYFRA 21-1. The procedure is simple and usually does not require any special preparation.

Elevated CYFRA 21-1 levels can suggest the presence of lung cancer or indicate cancer recurrence in patients who have already been treated. However, high levels may also be found in other malignancies and even some benign conditions, so results should always be interpreted in conjunction with other diagnostic findings.

CYFRA 21-1 is not typically used for screening in the general population because it is not specific enough. Its primary utility is in monitoring treatment response and detecting recurrence in patients with a known diagnosis of certain cancers.

While CYFRA 21-1 can be a useful marker in specific cancer cases, it is not definitive on its own. Non-cancerous conditions like liver diseases and infections may also cause elevated levels. Therefore, the test should always be considered alongside imaging studies and clinical evaluation.

Test code

3938

Specimen vol. and vacutainer information
SpecimenVacutainerVolume
SerumYellow Vacutainer1 ML

Specimen stability information

Serum

Collection instructions

Age + Gender + Clinical History Required. Samples Should Not Be Taken From Patients Receiving Therapy With High Biotin Doses (I.E. > 5 Mg/Day) Until At Least 8 Hours Following The Last Biotin Administration

Specimen rejection criteria

Test run frequency

Tuesday,Thursday,Saturday TIME - 11:00 , 15:00

Turn around time

Same Day

Performing locations

Department

  • Tumer Marker

CPT and Loinc codes

CYFRA 21-1, SERUM

3200